B Hampel1,2,3, K Kusejko1,2, R D Kouyos1,2, J Böni2, M Flepp4, M Stöckle5, A Conen6, C Béguelin7, P Künzler-Heule8, D Nicca8, A J Schmidt9, H Nguyen1,2, J Delaloye10, M Rougemont11, E Bernasconi12, A Rauch7, H F Günthard1,2, D L Braun1,2, J Fehr1,3. 1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 2. Institute of Medical Virology, University of Zurich, Zurich, Switzerland. 3. Department of Public Health, Epidemiology, Biostatistics and Public Health Institute, University of Zurich, Zurich, Switzerland. 4. Center of Infectious Diseases Zurich, Zurich, Switzerland. 5. Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University Basel, Basel, Switzerland. 6. Division of Infectious Diseases and Hospital Hygiene, Cantonal Hospital Aarau, Aarau, Switzerland. 7. Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland. 8. Institute of Nursing Science, University of Basel, and University Hospital Basel, Basel, Switzerland. 9. Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. 10. Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland. 11. Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland. 12. Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.
Abstract
OBJECTIVES: Chemsex refers to the use of sex-enhancing drugs among men who have sex with men (MSM) in combination with specific sexual and social behaviours. Longitudinal data on this development and the associated health risks are scarce. METHODS: Data on all recreational drugs reported in the Swiss HIV Cohort Study (SHCS) from 2007 to 2017 were collected. Drug use was analysed longitudinally for all drug classes. In addition, potential associations between patient characteristics and the consumption of methamphetamine, γ-hydroxybutric acid/γ-butyrolactone (GHB/GBL), 3,4-methylenedioxymethamphetamine (MDMA/XTC), cocaine and amphetamine were analysed. RESULTS: We analysed 166 167 follow-up entries for 12 527 SHCS participants, including 7101 free text field entries containing information about recreational drugs other than cannabis, cocaine and heroin. Overall, we observed a stable percentage (9.0%) of recreational drug use (excluding cannabis, amyl nitrite and prescription drugs). For MSM, however, there was an increase in overall drug use from 8.8% in 2007 to 13.8% in 2017, with particularly large increases for methamphetamine (from 0.2 to 2.4%; P < 0.001) and GHB/GBL (from 1.0 to 3.4%; P < 0.001). The use of each of the potentially sex-enhancing drugs methamphetamine, GHB/GBL, cocaine, XTC/MDMA and amphetamine was significantly associated with condomless sex with nonsteady partners, and higher prevalences of depression, syphilis and hepatitis C. CONCLUSIONS: The significant increase in the use of chemsex drugs among MSM in the SHCS and the strong association with coinfections and depression highlights the need for harm reduction programmes tailored to MSM. According to our results, improving knowledge about recreational drugs is important for all health care professionals working with people living with HIV.
OBJECTIVES: Chemsex refers to the use of sex-enhancing drugs among men who have sex with men (MSM) in combination with specific sexual and social behaviours. Longitudinal data on this development and the associated health risks are scarce. METHODS: Data on all recreational drugs reported in the Swiss HIV Cohort Study (SHCS) from 2007 to 2017 were collected. Drug use was analysed longitudinally for all drug classes. In addition, potential associations between patient characteristics and the consumption of methamphetamine, γ-hydroxybutric acid/γ-butyrolactone (GHB/GBL), 3,4-methylenedioxymethamphetamine (MDMA/XTC), cocaine and amphetamine were analysed. RESULTS: We analysed 166 167 follow-up entries for 12 527 SHCS participants, including 7101 free text field entries containing information about recreational drugs other than cannabis, cocaine and heroin. Overall, we observed a stable percentage (9.0%) of recreational drug use (excluding cannabis, amyl nitrite and prescription drugs). For MSM, however, there was an increase in overall drug use from 8.8% in 2007 to 13.8% in 2017, with particularly large increases for methamphetamine (from 0.2 to 2.4%; P < 0.001) and GHB/GBL (from 1.0 to 3.4%; P < 0.001). The use of each of the potentially sex-enhancing drugs methamphetamine, GHB/GBL, cocaine, XTC/MDMA and amphetamine was significantly associated with condomless sex with nonsteady partners, and higher prevalences of depression, syphilis and hepatitis C. CONCLUSIONS: The significant increase in the use of chemsex drugs among MSM in the SHCS and the strong association with coinfections and depression highlights the need for harm reduction programmes tailored to MSM. According to our results, improving knowledge about recreational drugs is important for all health care professionals working with people living with HIV.
Authors: Ada R Miltz; Alison J Rodger; Janey Sewell; Richard Gilson; Sris Allan; Christopher Scott; Tariq Sadiq; Paymaneh Farazmand; Jeffrey McDonnell; Andrew Speakman; Lorraine Sherr; Andrew N Phillips; Anne M Johnson; Simon Collins; Fiona C Lampe Journal: Int J Drug Policy Date: 2021-01-23
Authors: Liza Coyer; Anders Boyd; Udi Davidovich; Ward P H van Bilsen; Maria Prins; Amy Matser Journal: Addiction Date: 2021-09-22 Impact factor: 7.256
Authors: José Antonio Mata-Marín; Armando Abraham de Pablos-Leal; Stefan Mauss; Carla Ileana Arroyo-Anduiza; Mara Soraya Rodríguez-Evaristo; Luis Antonio Uribe-Noguéz; María de Los Ángeles Berrospe-Silva; Juan Carlos Lara-Castañeda; Edgar Pérez-Barragán; Jesús Gaytán-Martínez Journal: PLoS One Date: 2022-07-15 Impact factor: 3.752
Authors: Alexander Ring; Suraj Balakrishna; Frank Imkamp; Sara Burkard; Flurina Triet; Flurina Brunschweiler; Christina Grube; Rebecca Bodmer; Roger D Kouyos; Huldrych F Günthard; Dominique L Braun Journal: Open Forum Infect Dis Date: 2022-04-27 Impact factor: 4.423
Authors: Florian Bihl; Philip Bruggmann; Erika Castro Batänjer; Jean-Francois Dufour; Daniel Lavanchy; Beat Müllhaupt; Francesco Negro; Homie Razavi; Claude Scheidegger; David Semela; Nasser Semmo; Sarah Blach Journal: Liver Int Date: 2021-12-10 Impact factor: 8.754
Authors: Juan-Miguel Guerras; Patricia García de Olalla; María José Belza; Luis de la Fuente; David Palma; Jorge Del Romero; Jorge-Néstor García-Pérez; Juan Hoyos Journal: Harm Reduct J Date: 2021-08-06
Authors: F Hovaguimian; E Martin; M Reinacher; M Rasi; A J Schmidt; E Bernasconi; E Boffi El Amari; D L Braun; A Calmy; K Darling; V Christinet; C Depmeier; C Hauser; S Läuchli; J Notter; M Stoeckle; B Surial; P Vernazza; P Bruggmann; P Tarr; D Haerry; R Bize; N Low; A Lehner; J Böni; R D Kouyos; J S Fehr; B Hampel Journal: HIV Med Date: 2021-10-03 Impact factor: 3.094